Literature DB >> 3952731

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) modulates epidermal growth factor (EGF) binding to basal cells from a human keratinocyte cell line.

L G Hudson, W A Toscano, W F Greenlee.   

Abstract

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) modulates the proliferation, differentiation, or both, of epidermal keratinocytes in vivo and in culture. The growth of epidermal cells in culture is regulated by several biochemical mediators including epidermal growth factor (EGF). In this report the actions of TCDD on EGF binding in a basal cell population from a human keratinocyte cell line were examined. TCDD decreased the specific binding of 125I-EGF to basal cells by 40% within 96 hr. This reduction in EGF binding could not be attributed to changes in the state of differentiation as assessed by cell size and morphology, and cornified envelope competence, a marker of terminal differentiation. Modulation of EGF binding by TCDD was concentration-dependent (EC50 = 1 nM) and stereospecific, suggesting involvement of the Ah receptor. Scatchard analysis of EGF binding to the basal cells indicated a single class of high-affinity sites in both control (Kd = 0.14 nM) and treated (Kd = 0.11 nM) cultures and confirmed a decrease in the number of these sites in response to TCDD. The reduction in EGF binding correlated with a decrease in EGF-stimulated DNA synthesis and cell proliferation. Comparison of differentiation-competent squamous cell carcinoma (SCC) lines treated with TCDD supported an association between modulation of EGF binding and enhanced differentiation. The data indicate that basal cells are a target for TCDD. We propose that the modulation of EGF binding in basal keratinocytes by TCDD is one of the critical regulatory events resulting in enhanced differentiation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3952731     DOI: 10.1016/0041-008x(86)90283-8

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  8 in total

1.  Reproductive studies of C57B/6 male mice treated with TCDD-contaminated soils from a 2,4,5-trichlorophenoxyacetic acid manufacturing site.

Authors:  T H Umbreit; E J Hesse; M A Gallo
Journal:  Arch Environ Contam Toxicol       Date:  1988-03       Impact factor: 2.804

2.  EGF receptor expression and growth of psoriatic and normal human keratinocytes are modulated by 1.25 (OH)2-vitamin D3 ex vivo.

Authors:  A M Boisseau-Garsaud; P Donatien; C Margerin; A Taïeb
Journal:  Arch Dermatol Res       Date:  1996-07       Impact factor: 3.017

3.  TCDD induces dermal accumulation of keratinocyte-derived matrix metalloproteinase-10 in an organotypic model of human skin.

Authors:  K Nadira De Abrew; Christina L Thomas-Virnig; Cathy A Rasmussen; Elyse A Bolterstein; Sandy J Schlosser; B Lynn Allen-Hoffmann
Journal:  Toxicol Appl Pharmacol       Date:  2014-02-24       Impact factor: 4.219

4.  Actions of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on human epidermal keratinocytes in culture.

Authors:  W F Greenlee; K M Dold; R Osborne
Journal:  In Vitro Cell Dev Biol       Date:  1985-09

5.  Sequential actions of myotubularin lipid phosphatases regulate endosomal PI(3)P and growth factor receptor trafficking.

Authors:  Canhong Cao; Jonathan M Backer; Jocelyn Laporte; Edward J Bedrick; Angela Wandinger-Ness
Journal:  Mol Biol Cell       Date:  2008-06-04       Impact factor: 4.138

6.  Differential downregulation of e-cadherin and desmoglein by epidermal growth factor.

Authors:  Miquella G Chavez; Christian A Buhr; Whitney K Petrie; Angela Wandinger-Ness; Donna F Kusewitt; Laurie G Hudson
Journal:  Dermatol Res Pract       Date:  2012-01-16

7.  Ah receptor: relevance of mechanistic studies to human risk assessment.

Authors:  J C Cook; K W Gaido; W F Greenlee
Journal:  Environ Health Perspect       Date:  1987-12       Impact factor: 9.031

8.  Disruption of male reproductive tract development by administration of the xenoestrogen, nonylphenol, to male newborn rats.

Authors:  P C Lee
Journal:  Endocrine       Date:  1998-08       Impact factor: 3.925

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.